Navigation Links
Pharmaxis Reports Phase II Results for Aridol in COPD

tory Medicine: (2007) doi:10.1016/j.rmed.2007.01.08 4: Global initiative for chronic Obstructive Lung Disease (GOLD) 2006 ( http://www.goldcopd.com/ ) Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this press release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    Released through:


    United States:

     Brandon Lewis, Trout Group

     Tel:   +1-646-378-2915

     Email: 


    Australia:

     Virginia Nicholls

     Tel:   +61-0-417-610-824

     Email: 


    CONTACT:


    Alan Robertson - Chief Executive Officer

     Tel:   +61-2-9454-7200

     Email: 

blewis@troutgroup.com virginia.nicholls@pharmaxis.com.au arobertson@pharmaxis.com.au

CONTACT: Alan Robertson, Chief Executive Officer of Pharmax
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pharmaxis Reports Phase Results for Aridol COPD
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... NJ (PRWEB) , ... August 31, 2015 , ... ... Garden State Urology was formed in 2008, the result of a merger of ... principle that by working cooperatively, they could provide more cost-effective and higher quality ...
(Date:8/31/2015)... ... , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and ... Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. He ... sports in his senior year. He was inducted into the National Honor Society as ...
(Date:8/31/2015)... ... , ... Dr. Stewart Shofner of Shofner Vision Center explains what ... a comprehensive eye examination can diagnose amblyopia. According to the National Eye Institute ... approximately 2 to 3 out of every 100 children. , Dr. Shofner adds, ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... digital marketing communications company announced today that it has officially launched a new ... the new website and brand refresh are more closely aligned with the company’s ...
(Date:8/31/2015)... ... , ... Three Bakers Gluten Free Bakery launched the redesign of its website, ... information on their offering of gluten-free breads and pizzas, living without gluten, and resources ... us to share information about our gluten free product offerings, but also to really ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... Scientists have known which genes are linked ... University Baptist Medical Center have organized this information ... in studying the genetics of inflammatory diseases. , ... the researchers were able to systematically map out ...
... Limited,announced today that it will report efficacy data ... once-daily experimental cancer therapy CHR-2797 at the,forthcoming American ... oral aminopeptidase inhibitor currently in clinical development. The,company ... preclinical studies.,Details of the presentations are as follows:, ...
... Specifically for Resource-Limited ... Global Procurement Consortium, UPPSALA, Sweden, November 30 ... an agreement with the Clinton,Foundation HIV/AIDS Initiative (CHAI). Under ... to members of CHAI,s,Procurement Consortium at a discounted price. ...
... Pharmaceuticals is,pleased to announce that it received US ... strengths of 5mg, 10mg, 25mg and 50,mg, effective ... equivalent alternative to Urecholine(R) (a trademark of,Barr Laboratories)., ... Amneal, who is,one of the very first companies ...
... today,announced that the U.S. Drug Enforcement Administration (DEA) ... from,its Auburn, Wash. distribution center effective Dec. 3., ... the Washington facility,and only controlled substance shipments from ... of service to its customers., In an ...
... Smart Solutions to Keep Program,Accessible and Affordable, PHILADELPHIA, ... hosted a panel discussion with local voters to,address the ... the program after scheduled pay cuts go into effect ... the program to find a doctor. But with,Medicare enrollees ...
Cached Medicine News:Health News:Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility 2Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: